Since its inception, AMAR has worked to build an extensive patent portfolio for low-dose orally administered interferon. This portfolio consists of patents with claims that encompass method of use or treatment and composition of matter and manufacturing. AMAR believes that its patent protection will ensure its future commercial success within the field of low-dose orally administered interferon use. AMAR presently owns or licenses 9 issued patents, and has three pending patents related to low-dose orally administered interferon. One patent has also been issued to AMAR regarding Maxisal®, a dietary supplement marketed for relief of dry mouth. AMAR has vigorously enforced its patent position in the past, resulting in successful settlement. There are no current patent litigation proceedings involving AMAR.

TITLE: TREATMENT OF BACTERIAL INFECTION WITH ORAL INTERFERON-ALPHA

U.S. PATENT NO: 5,817,307

ISSUE DATE: OCTOBER 6, 1998

TERMINATION DATE: OCTOBER 6, 2015

US Patent No. 5,817,307 Independent Claims

TITLE: TREATMENT OF NEOPLASTIC DISEASE WITH ORAL  INTERFERON

U.S. PATENT NO: 5,824,300

ISSUE DATE: OCTOBER 20, 1998

TERMINATION DATE: OCTOBER 20, 2015

US Patent No. 5,824,300 Independent Claim

TITLE: TREATMENT OF AUTOIMMUNE DISORDERS WITH ORAL INTERFERON

U.S. PATENT NO: 5,846,526

ISSUE DATE: DECEMBER 8, 1998

TERMINATION DATE: DECEMBER 8, 2015 

US Patent No. 5,846,526 Idependent Claims

TITLE: TREATMENT OF HYPERALLERGENIC RESPONSE WITH ORAL INTERFERON 

U.S. PATENT NO: 5,882,640

ISSUE DATE: MARCH 16, 1999

TERMINATION DATE: MARCH 16, 2016

US Patent No. 5,882,640 Independent Claims

TITLE: LOW-DOSE ORAL ADMINISTRATION OF INTERFERONS

U.S. PATENT NO: 5,910,304

ISSUE DATE: JUNE 8, 1999

TERMINATION DATE: DECEMBER 8, 2010

US Patent No. 5,910,304 Independent Claims

TITLE: TREATMENT OF FIBROMYALGIA WITH LOW DOSES OF INTERFERON

U.S. PATENT NO: 6,036,949

ISSUE DATE: MARCH 14, 2000

TERMINATION DATE: MARCH 5, 2018

US Patent No. 6,036,949 Independent Claims

TITLE: INTERFERON-ALPHA MEDIATED UPREGULATION OF AQUAPORIN EXPRESSION 

U.S. PATENT NO: 6,506,377

ISSUE DATE: JANUARY 14, 2003

TERMINATION DATE: September 27, 2021

US Patent No. 6,506,377 Independent Claim

U.S. PATENT ASSIGNEE: KABUSHIKI KAISHA HAYASHIBARA, SEIBUTSU KAGAKU KENKYUJO, OKAYAMA, JAPAN

TITLE: SEMI-SOLID PHARMACEUTICAL AGENT AND PROCESS TO PRODUCE THE SAME

U.S. PATENT NUMBER: 5,489,577

ISSUE DATE: FEBRUARY 6, 1996

TERMINATION DATE: JUNE 28, 2013

US Patent No. 5,489,577 Independent Claims

TITLE: INTERFERON DOSAGE FORM AND METHOD THEREFOR

U.S. PATENT NO: 6,372,218 B1

ISSUE DATE: APRIL 16, 2002

TERMINATION DATE: APRIL 16, 2019 

US Patent No. 6,372,218 B1 Independent Claims